2-Substituted 6-(Het)aryl-7-deazapurine Ribonucleosides: Synthesis, Inhibition of Adenosine Kinases, and Antimycobacterial Activity. 2015

Vincent Malnuit, and Lenka Poštová Slavětínská, and Petr Nauš, and Petr Džubák, and Marián Hajdúch, and Jiřina Stolaříková, and Jan Snášel, and Iva Pichová, and Michal Hocek
Institute of Organic Chemistry and Biochemistry, Academy of Science Czech Republic, Gilead Sciences & IOCB Research Center, Flemingovo nám. 2, 16610 Prague 6 (Czech Republic) http://www.uochb.cas.cz/hocekgroup.

A series of 6-(hetero)aryl- or 6-methyl-7-deazapurine ribonucleosides bearing a substituent at position 2 (Cl, F, NH2, or CH3) were prepared by cross-coupling reactions at position 6 and functional group transformations at position 2. Cytostatic, antiviral, and antimicrobial activity assays were performed. The title compounds were observed to be potent and selective inhibitors of Mycobacterium tuberculosis adenosine kinase (ADK), but not human ADK; moreover, they were found to be non-cytotoxic. The antimycobacterial activities against M. tuberculosis, however, were only moderate. The reason for this could be due to either poor uptake through the cell wall or to parallel biosynthesis of adenosine monophosphate by the salvage pathway.

UI MeSH Term Description Entries
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000248 Adenosine Kinase An enzyme that catalyzes the formation of ADP plus AMP from adenosine plus ATP. It can serve as a salvage mechanism for returning adenosine to nucleic acids. EC 2.7.1.20. Kinase, Adenosine
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012263 Ribonucleosides Nucleosides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed)

Related Publications

Vincent Malnuit, and Lenka Poštová Slavětínská, and Petr Nauš, and Petr Džubák, and Marián Hajdúch, and Jiřina Stolaříková, and Jan Snášel, and Iva Pichová, and Michal Hocek
August 2010, ChemMedChem,
Vincent Malnuit, and Lenka Poštová Slavětínská, and Petr Nauš, and Petr Džubák, and Marián Hajdúch, and Jiřina Stolaříková, and Jan Snášel, and Iva Pichová, and Michal Hocek
February 2014, Journal of medicinal chemistry,
Vincent Malnuit, and Lenka Poštová Slavětínská, and Petr Nauš, and Petr Džubák, and Marián Hajdúch, and Jiřina Stolaříková, and Jan Snášel, and Iva Pichová, and Michal Hocek
January 2010, Journal of medicinal chemistry,
Vincent Malnuit, and Lenka Poštová Slavětínská, and Petr Nauš, and Petr Džubák, and Marián Hajdúch, and Jiřina Stolaříková, and Jan Snášel, and Iva Pichová, and Michal Hocek
October 2014, Journal of medicinal chemistry,
Vincent Malnuit, and Lenka Poštová Slavětínská, and Petr Nauš, and Petr Džubák, and Marián Hajdúch, and Jiřina Stolaříková, and Jan Snášel, and Iva Pichová, and Michal Hocek
January 2011, Bioorganic & medicinal chemistry,
Vincent Malnuit, and Lenka Poštová Slavětínská, and Petr Nauš, and Petr Džubák, and Marián Hajdúch, and Jiřina Stolaříková, and Jan Snášel, and Iva Pichová, and Michal Hocek
December 2015, Bioorganic & medicinal chemistry,
Vincent Malnuit, and Lenka Poštová Slavětínská, and Petr Nauš, and Petr Džubák, and Marián Hajdúch, and Jiřina Stolaříková, and Jan Snášel, and Iva Pichová, and Michal Hocek
July 2022, European journal of medicinal chemistry,
Vincent Malnuit, and Lenka Poštová Slavětínská, and Petr Nauš, and Petr Džubák, and Marián Hajdúch, and Jiřina Stolaříková, and Jan Snášel, and Iva Pichová, and Michal Hocek
April 2021, ACS infectious diseases,
Vincent Malnuit, and Lenka Poštová Slavětínská, and Petr Nauš, and Petr Džubák, and Marián Hajdúch, and Jiřina Stolaříková, and Jan Snášel, and Iva Pichová, and Michal Hocek
February 2021, ACS infectious diseases,
Vincent Malnuit, and Lenka Poštová Slavětínská, and Petr Nauš, and Petr Džubák, and Marián Hajdúch, and Jiřina Stolaříková, and Jan Snášel, and Iva Pichová, and Michal Hocek
October 2006, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!